Liminal BioSciences Inc (PLI) - Financial and Strategic SWOT Analysis Review

Liminal BioSciences Inc (PLI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the companys businesses and operations. The profile has been compiled to bring to you a clear and an unbiased view of the companys key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

- Business description A detailed description of the companys operations and business divisions.
- Corporate strategy Analysts summarization of the companys business strategy.
- SWOT Analysis A detailed analysis of the companys strengths, weakness, opportunities and threats.
- Company history Progression of key events associated with the company.
- Major products and services A list of major products, services and brands of the company.
- Key competitors A list of key competitors to the company.
- Key employees A list of the key executives of the company.
- Executive biographies A brief summary of the executives employment history.
- Key operational heads A list of personnel heading key departments/functions.
- Important locations and subsidiaries A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Liminal BioSciences Inc (Liminal) formerly known as ProMetic Life Sciences Inc, is a biopharmaceutical company that focuses on bioseparations, plasma-derived therapeutics and small-molecule drug development. The company develops products for the treatment for fibrosis and orphan diseases, including lung, liver, heart, kidney and pancreas. The company develops drug candidates based on two drug discovery platforms: small molecule therapeutics (PSMT) and plasma-derived therapeutics platforms. The company owns research and development facilities in the UK, the US and Canada and has manufacturing facilities in Canada and the Isle of Man and conducts business development activities in the US, Europe and Asia. Liminal is headquartered in Laval, Quebec, Canada.

Liminal BioSciences Inc Key Recent Developments

May 13,2020: Liminal Biosciences reports Q1 2020 results
Mar 22,2020: Liminal BioSciences comments on Coronavirus (COVID-19)
Mar 20,2020: Liminal Biosciences reports fourth quarter and 2019 year end results
Jan 13,2020: Liminal Biosciences outlines corporate priorities for 2020
Nov 28,2019: AMF concludes its review of the refinancing transactions completed by Liminal in April 2019

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the companys business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The companys core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company




Section 1 - About the Company
Liminal BioSciences Inc - Key Facts
Liminal BioSciences Inc - Key Employees
Liminal BioSciences Inc - Key Employee Biographies
Liminal BioSciences Inc - Major Products and Services
Liminal BioSciences Inc - History
Liminal BioSciences Inc - Company Statement
Liminal BioSciences Inc - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Section 2 Company Analysis
Company Overview
Liminal BioSciences Inc - Business Description
Business Segment: Bioseparations
Overview
Performance
Business Segment: Plasma-derived Therapeutics
Performance
Business Segment: Plasma-derived therapeutics segment
Overview
Business Segment: Small Molecule Therapeutics
Overview
Performance
Geographical Segment: Austria
Performance
Geographical Segment: China
Performance
Geographical Segment: Netherlands
Performance
Geographical Segment: Other Countries
Performance
Geographical Segment: South Korea
Performance
Geographical Segment: Sweden
Performance
Geographical Segment: Switzerland
Performance
Geographical Segment: United States
Performance
R&D Overview
Liminal BioSciences Inc - Corporate Strategy
Liminal BioSciences Inc - SWOT Analysis
SWOT Analysis - Overview
Liminal BioSciences Inc - Strengths
Liminal BioSciences Inc - Weaknesses
Liminal BioSciences Inc - Opportunities
Liminal BioSciences Inc - Threats
Liminal BioSciences Inc - Key Competitors
Section 3 Company Financial Ratios
Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts
Section 4 Companys Lifesciences Financial Deals and Alliances
Liminal BioSciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
Liminal BioSciences Inc, Pharmaceuticals & Healthcare, Deals By Type, 2014 to YTD 2020
Liminal BioSciences Inc, Recent Deals Summary
Section 5 Companys Recent Developments
May 13, 2020: Liminal Biosciences reports Q1 2020 results
Mar 22, 2020: Liminal BioSciences comments on Coronavirus (COVID-19)
Mar 20, 2020: Liminal Biosciences reports fourth quarter and 2019 year end results
Jan 13, 2020: Liminal Biosciences outlines corporate priorities for 2020
Nov 28, 2019: AMF concludes its review of the refinancing transactions completed by Liminal in April 2019
Nov 13, 2019: Liminal Biosciences announces key appointment to its leadership team
Nov 11, 2019: Liminal BioSciences reports its 2019 third quarter financial results and business highlights
Oct 03, 2019: Prometic Shareholders approve name change to Liminal BioSciences
Aug 12, 2019: Prometic reports financial results for second quarter 2019
May 08, 2019: Prometic strengthens its leadership with a new management structure and the appointment of three new directors
Section 6 Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

List Of Tables


Liminal BioSciences Inc, Key Facts
Liminal BioSciences Inc, Key Employees
Liminal BioSciences Inc, Key Employee Biographies
Liminal BioSciences Inc, Major Products and Services
Liminal BioSciences Inc, History
Liminal BioSciences Inc, Other Locations
Liminal BioSciences Inc, Subsidiaries
Liminal BioSciences Inc, Key Competitors
Liminal BioSciences Inc, Ratios based on current share price
Liminal BioSciences Inc, Annual Ratios
Liminal BioSciences Inc, Annual Ratios (Cont...1)
Liminal BioSciences Inc, Interim Ratios
Liminal BioSciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
Liminal BioSciences Inc, Pharmaceuticals & Healthcare, Deals By Type, 2014 to YTD 2020
Liminal BioSciences Inc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List Of Figures


Liminal BioSciences Inc, Performance Chart (2015 - 2019)
Liminal BioSciences Inc, Ratio Charts
Liminal BioSciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
Liminal BioSciences Inc, Pharmaceuticals & Healthcare, Deals by Type, 2014 to YTD 2020

Liminal BioSciences Inc (PLI) - Financial and Strategic SWOT Analysis Review

Liminal BioSciences Inc (PLI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the companys businesses and operations. The profile has been compiled to

USD 125 View Report

Interpace Biosciences Inc (IDXG) - Product Pipeline Analysis, 2020 Update

Interpace Biosciences Inc (Interpace Biosciences) formerly Interpace Diagnostics Group Inc, is a developer of molecular diagnostics tests. The company offers PancraGen, a DNA based molecular test that aids in pancreatic

USD 750 View Report

Akers Biosciences Inc (AKER) - Product Pipeline Analysis, 2020 Update

Akers Biosciences Inc (ABI) is a medical device company that develops, manufactures and supplies point-of-care screening and testing products. The company provides clinical diagnostics, safety diagnostics, and wellness products. ABI

USD 750 View Report

Fill The Form For Sample Request

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

There is no Reviews available